Preoperative left ventricular hypertrophy is associated with reduced patient survival after liver transplantation

作者：Felix Darstein, Christina König, Maria Hoppe‐Lotichius, Daniela Grimm, Johanna Knapstein, Jens Mittler, A. Zimmermann, G. Otto, Hauke Lang, Peter R. Galle, Tim Zimmermann · 发表于：Clinical Transplantation · 年份：2013 · DOI：10.1111/ctr.12304 · 被引用次数：28 · 研究领域：Liver Disease and Transplantation、Cardiovascular Function and Risk Factors、Pulmonary Hypertension Research and Treatments

UNLABELLED: Left ventricular hypertrophy (LVH) has been described in the context of cirrhotic cardiomyopathy. The influence of LVH on survival of liver transplant (LT) recipients has not been clarified. Therefore, we evaluated the effect of LVH on survival in LT recipients. In total, data from 352 LT patients were analyzed. LVH was diagnosed by echocardiographic measurement of left ventricular wall thickness before LT. Patients were followed up for a mean of 4.2 yr. LVH was diagnosed in 135 (38.4%) patients. Patients with LVH had significantly more frequently male gender (p = 0.046), diastolic dysfunction (p < 0.001), and hepatocellular carcinoma (HCC; p = 0.004). Furthermore, LVH patients were older (p < 0.001) and had a higher body mass index (BMI; p = 0.001). There was no difference in frequency of arterial hypertension, pre-transplant diabetes mellitus, or etiology of liver cirrhosis. Patients without LVH had a better survival (log rank: p = 0.05) compared with LVH patients. In a multivariate Cox regression LVH (p = 0.031), end-stage renal disease (ESRD; p = 0.003) and lack of arterial hypertension (p = 0.004) but not MELD score (p = 0.885) were associated with poorer survival. CONCLUSION: LVH is frequently diagnosed in patients on the waiting list and influences survival after LT.